IQVIA Holdings Inc. $IQV Holdings Decreased by Laurel Wealth Advisors LLC

Laurel Wealth Advisors LLC reduced its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 99.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,627 shares of the medical research company’s stock after selling 774,971 shares during the period. Laurel Wealth Advisors LLC’s holdings in IQVIA were worth $879,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of IQV. Physician Wealth Advisors Inc. boosted its holdings in shares of IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after purchasing an additional 134 shares during the period. Westside Investment Management Inc. lifted its position in IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after buying an additional 101 shares in the last quarter. Atlantic Union Bankshares Corp acquired a new stake in shares of IQVIA during the 3rd quarter valued at $36,000. Root Financial Partners LLC purchased a new position in IQVIA in the third quarter valued at about $43,000. Finally, Hantz Financial Services Inc. grew its stake in shares of IQVIA by 92.0% in the 3rd quarter. Hantz Financial Services Inc. now owns 240 shares of the medical research company’s stock valued at $46,000 after buying an additional 115 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Stifel Nicolaus lowered their price objective on IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research note on Thursday, January 22nd. Barclays decreased their target price on IQVIA from $230.00 to $210.00 and set an “equal weight” rating for the company in a research report on Friday, February 6th. Finally, Evercore reiterated an “outperform” rating and set a $225.00 price target on shares of IQVIA in a report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $231.80.

IQVIA Stock Up 5.0%

Shares of IQV opened at $179.09 on Monday. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. The company has a 50-day simple moving average of $212.19 and a 200-day simple moving average of $208.13. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $247.04. The firm has a market capitalization of $30.39 billion, a P/E ratio of 22.79, a P/E/G ratio of 1.72 and a beta of 1.40.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. During the same period in the previous year, the company posted $3.12 earnings per share. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.